Promaxo Holdings, Inc. and Zepp Health (NYSE: ZEPP) announced additional investments in Promaxo alongside plans to deepen their commercial partnership. The collaboration will involve sharing artificial intelligence resources, establishing new manufacturing opportunities, and pursuing China Food and Drug Administration regulatory approval.
Dr. Amit Vohra, Promaxo’s Founder and CEO, expressed satisfaction with the partnership: “We are pleased to have strategic investors, such as Zepp Health, as we commercialize our truly open MRI system to the broader physician office community.”
Promaxo intends to deploy the funds toward accelerating commercialization of artificial intelligence in imaging and image-guided interventions, maintaining its patient-centric approach to advance medical imaging, robotics, and AI applications.
Mike Yeung, Zepp Health’s COO, noted the strategic fit: “Zepp Health’s mission is to connect health with technology, and we see tremendous opportunity in imaging as we expand our footprint in the health technology space.”
Tim Houchin, VP of Business Development at Zepp Health, highlighted market expansion potential, indicating that diagnostic healthcare partnerships present new financial opportunities for industrial medical technology growth.